Nature Communications (Oct 2020)

Proline rich 11 (PRR11) overexpression amplifies PI3K signaling and promotes antiestrogen resistance in breast cancer

  • Kyung-min Lee,
  • Angel L. Guerrero-Zotano,
  • Alberto Servetto,
  • Dhivya R. Sudhan,
  • Chang-Ching Lin,
  • Luigi Formisano,
  • Valerie M. Jansen,
  • Paula González-Ericsson,
  • Melinda E. Sanders,
  • Thomas P. Stricker,
  • Ganesh Raj,
  • Kevin M. Dean,
  • Reto Fiolka,
  • Lewis C. Cantley,
  • Ariella B. Hanker,
  • Carlos L. Arteaga

DOI
https://doi.org/10.1038/s41467-020-19291-x
Journal volume & issue
Vol. 11, no. 1
pp. 1 – 15

Abstract

Read online

The 17q23 amplicon is associated with poor outcome in ER+ breast cancers, but the causal genes responsible endocrine resistance in this region are unclear. In this study, the authors demonstrate that PRR11 located at 17q23, is critical for conferring endocrine resistance through activation of PI3K signalling and therefore propose PI3K inhibition as a treatment for PRR11-amplified breast cancers.